Fatty Liver Disease disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: FTT001 MIFTS: 61	Fatty Liver Disease Categories: Cancer diseases, Gastrointestinal diseases, Genetic diseases, Liver diseases, Metabolic diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Fatty Liver Disease

MalaCards integrated aliases for Fatty Liver Disease:

Name: Fatty Liver Disease ¹¹ ⁴¹ ¹⁴ ⁷⁵

Alcoholic Fatty Liver ¹¹ ³¹ ³³

Fatty Liver, Alcoholic ⁴³ ⁷¹

Fatty Liver ⁴³ ⁷¹

Etoh Fatty Liver Metamorphosis ³³

Fatty Etoh Liver Necrosis ³³

Fatty Change of Liver ¹¹

Fatty Liver Alcoholic ⁵³

Steatosis of Liver ¹¹

Hepatic Lipidosis ¹¹

Etoh Fatty Liver ³³

Steatohepatitis ⁷¹

Classifications:

MalaCards categories:
Global: Metabolic diseases Genetic diseases Cancer diseases
Anatomical: Gastrointestinal diseases Liver diseases

See all MalaCards categories (disease lists)

ICD10: ³¹

Diseases of the digestive system

Diseases of liver

Alcoholic liver disease

Alcoholic fatty liver

Other diseases of liver

Fatty (change of) liver, not elsewhere classified

ICD11: ³³

Diseases of the digestive system

Diseases of liver

Alcoholic liver disease

Alcoholic fatty liver

External Ids:

Disease Ontology ¹¹ DOID:9452

ICD9CM ³⁴ 571.0

MeSH ⁴³ D005234 D005235

SNOMED-CT ⁶⁸ 371330000 50325005

ICD10 ³¹ K70.0 K76.0

ICD11 ³³ 1759668616

UMLS ⁷¹ C0015695 C0015696 C2711227

Sources

Summaries for Fatty Liver Disease

MedlinePlus: ⁴¹ What is fatty liver disease? Your liver is the largest organ inside your body. It helps your body digest food, store energy, and remove poisons. Fatty liver disease is a condition in which fat builds up in your liver. There are two main types: Nonalcoholic fatty liver disease (NAFLD) Alcoholic fatty liver disease, also called alcoholic steatohepatitis What is nonalcoholic fatty liver disease (NAFLD)? NAFLD is a type of fatty liver disease that is not related to heavy alcohol use. There are two kinds: Simple fatty liver, in which you have fat in your liver but little or no inflammation or liver cell damage. Simple fatty liver typically does not get bad enough to cause liver damage or complications. Nonalcoholic steatohepatitis (NASH), in which you have inflammation and liver cell damage, as well as fat in your liver. Inflammation and liver cell damage can cause fibrosis, or scarring, of the liver. NASH may lead to cirrhosis or liver cancer. What is alcoholic fatty liver disease? Alcoholic fatty liver disease is due to heavy alcohol use. Your liver breaks down most of the alcohol you drink, so it can be removed from your body. But the process of breaking it down can generate harmful substances. These substances can damage liver cells, promote inflammation, and weaken your body's natural defenses. The more alcohol that you drink, the more you damage your liver. Alcoholic fatty liver disease is the earliest stage of alcohol-related liver disease. The next stages are alcoholic hepatitis and cirrhosis. Who is at risk for fatty liver disease? The cause of nonalcoholic fatty liver disease (NAFLD) is unknown. Researchers do know that it is more common in people who: Have type 2 diabetes and prediabetes Have obesity Are middle aged or older (although children can also get it) Are Hispanic, followed by non-Hispanic whites. It is less common in African Americans. Have high levels of fats in the blood, such as cholesterol and triglycerides Have high blood pressure Take certain drugs, such as corticosteroids and some cancer drugs Have certain metabolic disorders, including metabolic syndrome Have rapid weight loss Have certain infections, such as hepatitis C Have been exposed to some toxins NAFLD affects about 25% of people in the world. As the rates of obesity, type 2 diabetes, and high cholesterol are rising in the United States, so is the rate of NAFLD. NAFLD is the most common chronic liver disorder in the United States. Alcoholic fatty liver disease only happens in people who are heavy drinkers, especially those who have been drinking for a long period of time. The risk is higher for heavy drinkers who are women, have obesity, or have certain genetic mutations. What are the symptoms of fatty liver disease? Both NAFLD and alcoholic fatty liver disease are usually silent diseases with few or no symptoms. If you do have symptoms, you may feel tired or have discomfort in the upper right side of your abdomen. How is fatty liver disease diagnosed? Because there are often no symptoms, it is not easy to find fatty liver disease. Your doctor may suspect that you have it if you get abnormal results on liver tests that you had for other reasons. To make a diagnosis, your doctor will use: Your medical history A physical exam Various tests, including blood and imaging tests, and sometimes a biopsy As part of the medical history, your doctor will ask about your alcohol use, to find out whether fat in your liver is a sign of alcoholic fatty liver disease or nonalcoholic fatty liver (NAFLD). He or she will also ask which medicines you take, to try to determine whether a medicine is causing your NAFLD. During the physical exam, your doctor will examine your body and check your weight and height. Your doctor will look for signs of fatty liver disease, such as: An enlarged liver Signs of cirrhosis, such as jaundice, a condition that causes your skin and whites of your eyes to turn yellow You will likely have blood tests, including liver function tests and blood count tests. In some cases you may also have imaging tests, like those that check for fat in the liver and the stiffness of your liver. Liver stiffness can mean fibrosis, which is scarring of the liver. In some cases you may also need a liver biopsy to confirm the diagnosis, and to check how bad the liver damage is. What are the treatments for fatty liver disease? Doctors recommend weight loss for nonalcoholic fatty liver. Weight loss can reduce fat in the liver, inflammation, and fibrosis. If your doctor thinks that a certain medicine is the cause of your NAFLD, you should stop taking that medicine. But check with your doctor before stopping the medicine. You may need to get off the medicine gradually, and you might need to switch to another medicine instead. There are no medicines that have been approved to treat NAFLD. Studies are investigating whether a certain diabetes medicine or Vitamin E can help, but more studies are needed. The most important part of treating alcohol-related fatty liver disease is to stop drinking alcohol. If you need help doing that, you may want to see a therapist or participate in an alcohol recovery program. There are also medicines that can help, either by reducing your cravings or making you feel sick if you drink alcohol. Both alcoholic fatty liver disease and one type of nonalcoholic fatty liver disease (nonalcoholic steatohepatitis) can lead to cirrhosis. Doctors can treat the health problems caused by cirrhosis with medicines, operations, and other medical procedures. If the cirrhosis leads to liver failure, you may need a liver transplant. What are some lifestyle changes that can help with fatty liver disease? If you have any of the types of fatty liver disease, there are some lifestyle changes that can help: Eat a healthy diet, limiting salt and sugar, plus eating lots of fruits, vegetables, and whole grains Get vaccinations for hepatitis A and B, the flu and pneumococcal disease. If you get hepatitis A or B along with fatty liver, it is more likely to lead to liver failure. People with chronic liver disease are more likely to get infections, so the other two vaccinations are also important. Get regular exercise, which can help you lose weight and reduce fat in the liver Talk with your doctor before using dietary supplements, such as vitamins, or any complementary or alternative medicines or medical practices. Some herbal remedies can damage your liver.

MalaCards based summary: Fatty Liver Disease, also known as alcoholic fatty liver, is related to non-alcoholic fatty liver disease and fatty liver disease 1. An important gene associated with Fatty Liver Disease is NAFLD1 (Fatty Liver Disease 1, Susceptiblity To), and among its related pathways/superpathways are Signal Transduction and IL-9 Signaling Pathways. The drugs Tocopherol and Losartan have been mentioned in the context of this disorder. Affiliated tissues include liver, skeletal muscle and kidney, and related phenotypes are Increased shRNA abundance (Z-score > 2) and homeostasis/metabolism

Disease Ontology: ¹¹ A lipid storage disease characterized by the accumulation of large vacuoles of triglyceride fat in liver cells via the process of steatosis.

Wikipedia: ⁷⁵ Fatty liver disease (FLD), also known as hepatic steatosis, is a condition where excess fat builds up in... more...

Sources

Related Diseases for Fatty Liver Disease

Diseases in the Fatty Liver Disease family:

Fatty Liver Disease 1

Fatty Liver Disease 2

Diseases related to Fatty Liver Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1044)

#	Related Disease	Score	Top Affiliating Genes
1	non-alcoholic fatty liver disease	34.2	TNF SREBF1 PPARA PNPLA3 NR1H4 LEPR
2	fatty liver disease 1	33.8	PNPLA3 NAFLD1
3	liver disease	33.6	XBP1 TNF SREBF1 PPARA PNPLA3 NR1H4
4	alcohol dependence	33.5	TNF PPARA LEP INS CYP2E1
5	non-alcoholic steatohepatitis	33.4	TNF SREBF1 PPARA PNPLA3 NR1H4 LEP
6	abdominal obesity-metabolic syndrome 1	32.8	PPARA NR1H4 LEPR LEP INS ADIPOQ
7	alcohol use disorder	32.8	TNF INS IL6 CYP2E1
8	type 2 diabetes mellitus	32.7	XBP1 TNF SREBF1 PPARA PNPLA3 NR1H4
9	lipid metabolism disorder	32.7	TNF SREBF1 PPARA NR1H4 LEPR LEP
10	hyperlipidemia, familial combined, 3	32.5	PPARA LEPR INS ADIPOQ
11	leptin deficiency or dysfunction	32.5	TNF SREBF1 PPARA LEPR LEP IRS2
12	body mass index quantitative trait locus 11	32.4	TNF SREBF1 PPARA PNPLA3 NR1H4 LEPR
13	prediabetes syndrome	32.3	LEPR LEP IRS1 INS ADIPOQ
14	cardiovascular system disease	32.2	TNF PPARA NR1H4 LEPR LEP INS
15	atherosclerosis susceptibility	32.2	TNF PPARA LEP INS IL6 CCL2
16	liver cirrhosis	32.2	TNF PNPLA3 MALAT1 LEPR LEP INS
17	apnea, obstructive sleep	32.2	TNF LEP INS IL6 ADIPOQ
18	polycystic ovary syndrome	32.1	LEP IRS2 IRS1 INS ADIPOQ
19	sleep apnea	32.1	TNF LEPR LEP INS IL6 CCL2
20	hyperinsulinism	32.1	SREBF1 PPARA LEPR LEP IRS2 IRS1
21	chronic kidney disease	32.1	TNF LEP INS IL6 ADIPOQ
22	glucose intolerance	32.1	TNF LEPR LEP IRS1 INS IL6
23	nutritional deficiency disease	32.0	LEPR LEP IL6 ADIPOQ
24	kidney disease	32.0	TNF LEP INS IL6 CYP2E1 CCL2
25	hepatocellular carcinoma	32.0	XBP1 TNF SREBF1 PPARA MALAT1 LEPR
26	familial hyperlipidemia	31.9	PPARA LEP INS ADIPOQ
27	diabetes mellitus	31.9	XBP1 TNF SREBF1 PPARA PNPLA3 NR1H4
28	arteries, anomalies of	31.9	TNF INS IL6 CCL2 ADIPOQ
29	lipoprotein quantitative trait locus	31.9	TNF PPARA IRS1 INS IL6 CCL2
30	adult syndrome	31.8	TNF PPARA LEP INS IL6 ADIPOQ
31	type 1 diabetes mellitus	31.7	TNF LEPR LEP INS IL6
32	hyperglycemia	31.7	TNF MALAT1 LEP IRS2 IRS1 INS
33	inflammatory bowel disease	31.7	XBP1 TNF PPARA NR1H4 LEP IRS2
34	hypertension, essential	31.7	TNF SREBF1 PPARA LEPR LEP IRS1
35	vascular disease	31.7	TNF NR1H4 LEP INS IL6 CCL2
36	gestational diabetes	31.7	TNF LEPR LEP IRS2 IRS1 INS
37	bowel dysfunction	31.7	TNF INS IL6
38	overnutrition	31.7	TNF SREBF1 PPARA LEPR LEP IRS1
39	alcoholic hepatitis	31.6	TNF IL6 CYP2E1 CCL2
40	severe covid-19	31.6	TNF IL6 CCL2
41	disseminated intravascular coagulation	31.6	TNF IL6 CCL2
42	primary biliary cholangitis	31.5	TNF PPARA PNPLA3 NR1H4 INS IL6
43	alcoholic liver cirrhosis	31.5	TNF INS IL6 CYP2E1
44	celiac disease 1	31.5	TNF LEP INS IL6 CCL2
45	varicose veins	31.5	TNF IL6 CCL2
46	proteasome-associated autoinflammatory syndrome 1	31.5	TNF PPARA INS IL6 CCL2 ADIPOQ
47	choline deficiency disease	31.5	SREBF1 PPARA NR1H4 INS
48	gastroesophageal reflux	31.5	TNF IL6 CCL2 ADIPOQ
49	cholelithiasis	31.4	NR1H4 LEP INS
50	conn's syndrome	31.4	TNF LEP INS IL6 ADIPOQ

Comorbidity relations with Fatty Liver Disease via Phenotypic Disease Network (PDN):

Alcohol Use Disorder	Alcoholic Hepatitis
Alcoholic Liver Cirrhosis

Graphical network of the top 20 diseases related to Fatty Liver Disease:

Sources

Symptoms & Phenotypes for Fatty Liver Disease

GenomeRNAi Phenotypes related to Fatty Liver Disease according to GeneCards Suite gene sharing:

²⁵ (show all 15)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Increased shRNA abundance (Z-score > 2)	GR00366-A-104	9.53	LEP
2	Increased shRNA abundance (Z-score > 2)	GR00366-A-110	9.53	IRS2
3	Increased shRNA abundance (Z-score > 2)	GR00366-A-111	9.53	IRS2
4	Increased shRNA abundance (Z-score > 2)	GR00366-A-112	9.53	LEP
5	Increased shRNA abundance (Z-score > 2)	GR00366-A-113	9.53	LEP
6	Increased shRNA abundance (Z-score > 2)	GR00366-A-127	9.53	LEP XBP1
7	Increased shRNA abundance (Z-score > 2)	GR00366-A-137	9.53	XBP1
8	Increased shRNA abundance (Z-score > 2)	GR00366-A-138	9.53	XBP1
9	Increased shRNA abundance (Z-score > 2)	GR00366-A-199	9.53	LEP
10	Increased shRNA abundance (Z-score > 2)	GR00366-A-206	9.53	NR1H3
11	Increased shRNA abundance (Z-score > 2)	GR00366-A-213	9.53	LEP
12	Increased shRNA abundance (Z-score > 2)	GR00366-A-216	9.53	LEP
13	Increased shRNA abundance (Z-score > 2)	GR00366-A-29	9.53	XBP1
14	Increased shRNA abundance (Z-score > 2)	GR00366-A-38	9.53	NR1H3
15	Increased shRNA abundance (Z-score > 2)	GR00366-A-55	9.53	LEP

MGI Mouse Phenotypes related to Fatty Liver Disease:

⁴⁵ (show all 18)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.46	ADIPOQ CCL2 CYP2E1 IL6 INS IRS1
2	liver/biliary system	MP:0005370	10.44	ADIPOQ CCL2 CYP2E1 IL6 INS IRS1
3	nervous system	MP:0003631	10.35	ADIPOQ CCL2 IL6 INS IRS2 LEP
4	adipose tissue	MP:0005375	10.34	ADIPOQ CCL2 IL6 INS IRS1 IRS2
5	growth/size/body region	MP:0005378	10.34	ADIPOQ CCL2 CYP2E1 IL6 INS IRS1
6	muscle	MP:0005369	10.33	ADIPOQ CCL2 IL6 INS IRS1 IRS2
7	cellular	MP:0005384	10.31	ADIPOQ CCL2 IL6 INS IRS1 IRS2
8	cardiovascular system	MP:0005385	10.28	ADIPOQ CCL2 CYP2E1 IL6 INS IRS1
9	neoplasm	MP:0002006	10.27	ADIPOQ CCL2 CYP2E1 IL6 LEP LEPR
10	endocrine/exocrine gland	MP:0005379	10.22	ADIPOQ IL6 INS IRS1 IRS2 LEP
11	immune system	MP:0005387	10.2	ADIPOQ CCL2 IL6 INS IRS1 IRS2
12	behavior/neurological	MP:0005386	10.18	ADIPOQ CCL2 CYP2E1 IL6 INS IRS2
13	renal/urinary system	MP:0005367	10.16	ADIPOQ IL6 INS IRS2 LEP LEPR
14	digestive/alimentary	MP:0005381	10.06	CCL2 IL6 INS LEP LEPR NR1H4
15	skeleton	MP:0005390	10	ADIPOQ CCL2 CYP2E1 IL6 INS IRS1
16	mortality/aging	MP:0010768	9.86	ADIPOQ CCL2 CYP2E1 IL6 INS IRS1
17	vision/eye	MP:0005391	9.85	CCL2 IL6 INS IRS1 IRS2 LEP
18	integument	MP:0010771	9.36	ADIPOQ CCL2 IL6 INS IRS2 LEP

Sources

Drugs & Therapeutics for Fatty Liver Disease

Drugs for Fatty Liver Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 431)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Tocopherol

Approved, Investigational

Phase 4

1406-66-2

Losartan

Approved

Phase 4

114798-26-4

3961

Angiotensin II

Approved, Investigational

Phase 4

68521-88-0, 11128-99-7, 4474-91-3

172198

Milk thistle

Approved, Experimental, Investigational

Phase 4

65666-07-1

Simvastatin

Approved

Phase 4

79902-63-9

54454

Telmisartan

Approved, Investigational

Phase 4

144701-48-4

65999

Amlodipine

Approved

Phase 4

88150-42-9

2162

Perindopril

Approved

Phase 4

82834-16-0, 107133-36-8

107807

Midazolam

Approved, Illicit

Phase 4

59467-70-8

4192

Alogliptin

Approved

Phase 4

850649-61-5

11450633

Glucagon

Approved

Phase 4

16941-32-5

16133228 16186314

Liraglutide

Approved

Phase 4

204656-20-2

44147092 16134956

Gliclazide

Approved

Phase 4

21187-98-4

3475

Glimepiride

Approved

Phase 4

93479-97-1

3476

Ezetimibe

Approved

Phase 4

163222-33-1

150311

Ursodeoxycholic acid

Approved, Investigational

Phase 4

128-13-2

31401

Rifampicin

Approved

Phase 4

13292-46-1

135512673 5381226 135900090

Insulin aspart

Approved

Phase 4

116094-23-6

16132418

Insulin detemir

Approved

Phase 4

169148-63-4

16137271

Pentoxifylline

Approved, Investigational

Phase 4

6493-05-6

4740

Selenium

Approved, Investigational, Vet_approved

Phase 4

7783-07-5, 7782-49-2

533

Adenosine

Approved, Investigational

Phase 4

58-61-7

60961

Phentermine

Approved, Illicit

Phase 4

122-09-8

4771

Montelukast

Approved

Phase 4

158966-92-8

5281040

Orlistat

Approved, Investigational

Phase 4

96829-58-2

3034010

Efavirenz

Approved, Investigational

Phase 4

154598-52-4

64139

Benzocaine

Approved, Investigational

Phase 4

1994-09-7, 94-09-7

2337

Tannic acid

Approved

Phase 4

1401-55-4

16129878 16129778

Sorbitol

Approved, Investigational

Phase 4

69-65-8, 50-70-4

453 6251 5780

Dapagliflozin

Approved

Phase 4

461432-26-8

9887712

Estradiol

Approved, Investigational, Vet_approved

Phase 4

50-28-2

5757

Polyestradiol phosphate

Approved

Phase 4

28014-46-2

Methyltestosterone

Approved

Phase 4

58-18-4

6010

Testosterone undecanoate

Approved, Investigational

Phase 4

5949-44-0

21873174 65157

Testosterone enanthate

Approved

Phase 4

315-37-7

9416

Testosterone

Approved, Investigational

Phase 4

58-22-0

5408 6013

Cetrorelix

Approved, Investigational

Phase 4

120287-85-6

25074887

Empagliflozin

Approved

Phase 4

864070-44-0

73151030 11949646

Dulaglutide

Approved, Investigational

Phase 4

923950-08-7

Ketotifen

Approved

Phase 4

34580-14-8, 34580-13-7

3827

Histamine

Approved, Investigational

Phase 4

51-45-6

774

Alendronic acid

Approved

Phase 4

121268-17-5, 66376-36-1

2088

Calcium carbonate

Approved, Investigational

Phase 4

471-34-1

Denosumab

Approved

Phase 4

615258-40-7

Metformin

Approved

Phase 4

1115-70-4, 657-24-9

4091

Pioglitazone

Approved, Investigational

Phase 4

111025-46-8

4829

Insulin glargine

Approved

Phase 4

160337-95-1

118984454

Rosiglitazone

Approved, Investigational

Phase 4

122320-73-4, 155141-29-0

77999

Zinc cation

Approved, Experimental, Investigational

Phase 4

7440-66-6, 23713-49-7

32051

Rifaximin

Approved, Investigational

Phase 4

80621-81-4

46783403 6436173

Interventional clinical trials:

(show top 50) (show all 1306)

#	Name	Status	NCT ID	Phase	Drugs
1	THE EFFECT OF DUAL TREATMENT WITH L-CARNITINE AND MAGNESIUM ON Patients With Non Alcoholic Fatty Liver Disease	Unknown status	NCT01956825	Phase 4
2	Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease	Unknown status	NCT00941642	Phase 4	Lovaza;placebo control
3	Comparison of The Effects of Thiazolidinediones(TZD), Sodium- Glucose Cotransporter 2 Inhibitors(SGLT2i) Alone and TZD / SGLT2i Combination Therapy on Non-alcoholic Fatty Liver Disease in Type 2 Diabetic Patients With Fatty Liver	Unknown status	NCT03646292	Phase 4	Pioglitazone;Empagliflozin;Combination of pioglitazone and empagliflozin
4	Evaluation of Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial	Unknown status	NCT02213224	Phase 4	Perindopril;Telmisartan;Amlodipine
5	Effect of Metadoxine on Oxidative Stress in Non-alcoholic Fatty Liver Disease Prediabetic Mexican Patients	Unknown status	NCT02051842	Phase 4	Metadoxine
6	S.P.PRO LIVER POWDER is Used to Improve Liver and Metabolic Indexes in People With Non-alcoholic Fatty Liver Disease	Unknown status	NCT04718051	Phase 4	Shen Pu Yang Gan Wan;Placebo
7	The Effect of Consecutive Fecal Microbiota Transplantation on Non-Alcoholic Fatty Liver Disease (NAFLD) - a Randomized-controlled Trial -	Unknown status	NCT04465032	Phase 4
8	An Randomized Open Label Trial on the Impact of 24 Weeks of Atorvastatin Therapy on Liver Fat Content and Abdominal Fat Content in Patients With Type 2 Diabetes Combined With High LDL-C and Non-alcoholic Fatty Liver Disease	Unknown status	NCT01720719	Phase 4	atorvastatin;Vitamin E
9	The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes	Unknown status	NCT02964715	Phase 4	Empagliflozin
10	A Randomised Controlled Trial of Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis	Unknown status	NCT01950884	Phase 4	Ezetimibe
11	Pilot Study to Assess the Antiviral Activity and Safety of Besifovir Dipivoxil 150mg and L-carnitine 660mg Compared to Tenofovir Alafenamide 25mg in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver	Unknown status	NCT03604016	Phase 4	Besifovir dipivoxil;L-carnitine;Tenofovir Alafenamide
12	Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis: a Multicentre, Randomised, Placebo-controlled Trial	Unknown status	NCT03198572	Phase 4	Placebo;Berberine
13	To Evaluate the Effect of Nesinaact on Non-alcoholic Steatohepatitis Through MRI and Liver Fibroscan in Patients With Type 2 Diabetes: A Prospective, Open-Label, Single-Arm, Single-Center Clinical Study	Unknown status	NCT03950505	Phase 4	Nesinaact 25/15 (Alogliptin benzoate 25mg, pioglitazone hydrochloride 15mg) treatment for 24 weeks
14	Randomized Study Comparing Switching to Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Monoinfected Patients Impact on Fatty Liver and Liver Fibrosis Assessed by Noninvasive Diagnostic Methods	Unknown status	NCT02210715	Phase 4	Isentress.
15	Complex Imaging Assessment of Steatosis in Patients Under Treatment With Combination Silimarin, Phyllanthus Niruri and Choline	Unknown status	NCT02669641	Phase 4
16	Effect of Liraglutide on Fatty Liver Content Evaluated by Proton-spectroscopy (1H-spectroscopy) and Lipoprotein Kinetic, in Patients With Type 2 Diabetes	Unknown status	NCT02721888	Phase 4	Liraglutide;MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
17	Ultrasonographic Modification of Liver Steatosis and Visceral Fat Induced by Treatment With Losartan and Simvastatin in Hypertensive Normocholesterolemic Obese Patients	Unknown status	NCT00669435	Phase 4	Losartan + Simvastatin;Amlodipine + Simvastatin
18	Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients-A Randomized, Double-Blinded, Controlled Trial	Unknown status	NCT01148576	Phase 4	entecavir;essentiale + entecavir;Vitamin E + entecavir
19	Efficacy of Liraglutide vs. Sitagliptin vs. Insulin Glargine Per Day on Liver Fat When Combined With Metformin in T2DM Subjects With Non-alcoholic Fatty-liver Disease	Completed	NCT02147925	Phase 4	Liraglutide combined with metformin;Insulin glargine combined with metformin;Sitagliptin combined with metformin
20	Comparison of Efficacy of Liraglutide, Metformin and Gliclazide MR on Hepatic Lipid Content in Patients With Type 2 Diabetes (T2DM) and Non-alcoholic Fatty Liver (NAFLD)	Completed	NCT03068065	Phase 4	Liraglutide;Metformin;Gliclazide
21	Efficacy of Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets on the Patients With Newly Diagnosed Type 2 Diabetes Mellitus Combined With Non-alcoholic Fatty Liver Disease：an Multicenter，Randomized, Double-blind, Parallel- Controlled Study.	Completed	NCT03796975	Phase 4	Combination of Pioglitazone and Metformin Tablets;Metformin Hydrochloride Tablets
22	Pleiotropic Effects and Safety of Sodium Glucose Co-transporter 2 Inhibitor Versus Sulfonylurea in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver	Completed	NCT02649465	Phase 4	Tofogliflozin;Glimepiride
23	Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes	Completed	NCT02637973	Phase 4	Empagliflozin;Placebo
24	A Multicenter, Double-blind, Active-controlled, Randomized, Parallel, Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Evogliptin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases	Completed	NCT03910361	Phase 4	Evogliptin;Pioglitazone
25	A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD	Completed	NCT02285205	Phase 4	Oral administration of Lobeglitazone
26	The Effects of Purified n-3 Fatty Acids on Serum Fibrosis Markers and Cardiovascular Risk Markers in a Randomized Placebo Controlled Trial in Patients With Non Alcoholic Fatty Liver Disease	Completed	NCT00760513	Phase 4	OMACOR;Placebo oral capsule
27	Exenatide BID Compared With Insulin Glargine to Change Liver Fat Content in Non-alcoholic Fatty-liver Disease Patients With Type 2 Diabetes	Completed	NCT02303730	Phase 4	Exenatide;insulin glargine
28	PXR-aktivaation Vaikutus Maksan Rasvoittumiseen	Completed	NCT02329405	Phase 4	Rifampicin;Placebo
29	A New Treatment Strategy of Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD)	Completed	NCT01006889	Phase 4	Exenatide
30	Use of Vitamin D in Treatment of Non-Alcoholic Fatty Liver Disease Detected by Transient Elastography	Completed	NCT04038853	Phase 4	1,25-Dihydroxyvitamin D;Placebo
31	Long-term Role of Pioglitazone in Non-Alcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes Mellitus (T2DM).	Completed	NCT00994682	Phase 4	Pioglitazone study drug;Placebo;Pioglitazone Open Label
32	A Randomized, Prospective, Open Label, Active Control, Phase IV Study to Evaluate the Effects of Statin Monotherapy or Statin / Ezetimibe Combination Therapy on Hepatic Steatosis in Patients With Hyperlipidemia and Nonalcoholic Fatty Liver Disease	Completed	NCT03434613	Phase 4	Rosuvastatin;Rosuvastatin/ezetimibe combination
33	Effects of Exenatide (Byetta®) on Biochemical and Histological Parameters of Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH)	Completed	NCT01208649	Phase 4	Exenatide
34	Impact of Short-term Fructose-enriched Diet on Serum Metabolome by Normal- and Over-weighed Women.	Completed	NCT03444233	Phase 4
35	The Effect of Vitamin D Supplementation on the Glycemic Control and Non-alcoholic Fatty Liver Disease in Type 2 Diabetes	Completed	NCT01854463	Phase 4	Vitamin D3;placebo
36	The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease: Investigator Initiated Randomized Placebo-controlled Double-blind, Pilot Study	Completed	NCT03222206	Phase 4	Salsalate
37	Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone	Completed	NCT02875821	Phase 4	Ipragliflozin;metformin with pioglitazone
38	A Randomized Study to Compare the Efficacy of Vitamin E, Ursodeoxycholic Acid and Pentoxyfylline on Egyptian Patients With Non-alcoholic Fatty Liver Disease Using (IL6 and CCL2) as a Predictors of Non-alcoholic Steatohepatitis	Completed	NCT04977661	Phase 4	Vitamin E;Ursodeoxycholic acid;Pentoxifylline
39	Effectiveness and Tolerability of Phentermine in the Reduction of Intrahepatic Fat Infiltration, Adipose Tissue and Postoperative Complications in Patients Under Bariatric Surgery	Completed	NCT03849729	Phase 4	Phentermine
40	Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH)	Completed	NCT00160407	Phase 4	Orlistat (Xenical)
41	NAFLD in T2DM: Prevalence in Hispanics and Role of Treatment	Completed	NCT01002547	Phase 4	pioglitazone-placebo;pioglitazone;Vitamin E-placebo
42	Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH)	Completed	NCT00227110	Phase 4	Pioglitazone;Placebo
43	Clinical Study Evaluating the Efficacy and Safety of Montelukast in the Treatment of Non-Alcoholic Steatohepatitis (NASH)	Completed	NCT04537780	Phase 4	Montelukast
44	Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus and South Asian Descent	Completed	NCT02660047	Phase 4	Liraglutide;Liraglutide - Placebo
45	MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism in Patients With Prostate Cancer: Orchiectomy vs. Triptorelin	Completed	NCT02102646	Phase 4	Triptorelin
46	Effect on Liver Fat, Adipose Tissue and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to Once Daily Raltegravir in HIV+ Patients With Body Mass Index Over 25 kg/m2 and With at Least One Metabolic Syndrome Component	Completed	NCT03374358	Phase 4	Raltegravir
47	A Multi-Centered, Prospective, Randomized, Placebo-Controlled Clinical Trial for the Treatment of Significant Steatosis or NASH With Xenical Followed by Treatment of Hepatitis C (HCV) With PEG-Interferon Alpha-2a/Copegus	Completed	NCT00207311	Phase 4	Xenical, Pegasys, Copegus
48	Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus	Completed	NCT01761318	Phase 4	Liraglutide;Liraglutide - Placebo
49	Evaluating the Effect of Pentoxifylline, Ursodiol, and Empagliflozin on Fatty Liver of Patients With Type-2 Diabetes	Completed	NCT04910178	Phase 4	Empagliflozin 25 MG;Ursodeoxycholic acid;Pentoxifylline 400 MG
50	Biochemical and Echosonographic Impacts Using Siliphos-Selenium-Methionine-Alpha Lipoic Acid + Metformin Versus Metformin in Patients With Fatty Liver and Steatohepatitis	Completed	NCT01650181	Phase 4	Metformin

Search NIH Clinical Center for Fatty Liver Disease

Cochrane evidence based reviews: fatty liver

Sources

Genetic Tests for Fatty Liver Disease

Sources

Anatomical Context for Fatty Liver Disease

Organs/tissues related to Fatty Liver Disease:

MalaCards : Liver, Skeletal Muscle, Kidney, Skin, Ovary, Endothelial, Heart

Sources

Publications for Fatty Liver Disease

Articles related to Fatty Liver Disease:

(show top 50) (show all 30413)

#	Title	Authors	PMID	Year
1	The Synergic Effect of a Nutraceutical Supplementation Associated to a Mediterranean Hypocaloric Diet in a Population of Overweight/Obese Adults with NAFLD. ⁶² ⁴¹	Chiurazzi M...Lonardo MS	36432436	2022
2	Change lifestyle modification plan/transtheoretical model in non-alcoholic simple fatty liver disease: a pilot randomized study. ⁶² ⁴¹	Li L...Zhang Y	36424552	2022
3	Predicting Factors for Metabolic Non-Response to a Complex Lifestyle Intervention-A Replication Analysis to a Randomized-Controlled Trial. ⁶² ⁴¹	Kabisch S...Pfeiffer AFH	36432409	2022
4	Adiponectin: a key adipokine in alcoholic fatty liver. ⁵³ ⁶²	You M...Rogers CQ	19491377	2009
5	The multi-hit process and the antagonistic roles of tumor necrosis factor-alpha and adiponectin in non alcoholic fatty liver disease. ⁵³ ⁶²	Polyzos SA...Zavos Ch	19561788	2009
6	Molecular mechanisms of alcoholic fatty liver. ⁵³ ⁶²	Purohit V...Song BJ	19032584	2009
7	Adiponectin and alcoholic fatty liver disease. ⁵³ ⁶²	Rogers CQ...You M	18709650	2008
8	Role of adiponectin in the protective action of dietary saturated fat against alcoholic fatty liver in mice. ⁵³ ⁶²	You M...Crabb DW	16108051	2005
9	Adiponectin and alcoholic fatty liver: Is it, after all, about what you eat? ⁵³ ⁶²	Anania FA	16116627	2005
10	Role of fatty liver, dietary fatty acid supplements, and obesity in the progression of alcoholic liver disease: introduction and summary of the symposium. ⁵³ ⁶²	Purohit V...Coates PM	15670659	2004
11	Clinical features and risk factors of patients with fatty liver in Guangzhou area. ⁵³ ⁶²	Chen QK...Zhou XD	15040041	2004
12	Relationship between genetic polymorphism of cytochrome P450IIE1 and fatty liver. ⁵³ ⁶²	Piao YF...Shi Y	14606109	2003
13	Adverse Effect of Nonalcoholic Fatty Liver Disease on the Therapeutic Response in Patients with Chronic Hepatitis B. ⁶²	Zhang S...Shang J	36406311	2023
14	The Gut Microbiome and Ferroptosis in MAFLD. ⁶²	Ji J...Guo C	36406312	2023
15	Triclocarban and triclosan exacerbate high-fat diet-induced hepatic lipid accumulation at environmental related levels: The potential roles of estrogen-related receptors pathways. ⁶²	Li X...Cao LY	36372182	2023
16	USP10 Alleviates Palmitic Acid-induced Steatosis through Autophagy in HepG2 Cells. ⁶²	Xin SL...Yu YY	36406315	2023
17	Prognostic Relevance of Metabolic Dysfunction-associated Steatohepatitis for Patients with Chronic Hepatitis B. ⁶²	Rugivarodom M...Charatcharoenwitthaya P	36406326	2023
18	A turn-on fluorescent probe based on ESIPT and AIEE mechanisms for the detection of butyrylcholinesterase activity in living cells and in non-alcoholic fatty liver of zebrafish. ⁶²	Pei X...Chen X	36327810	2023
19	Gellan gum prevents non-alcoholic fatty liver disease by modulating the gut microbiota and metabolites. ⁶²	Do MH...Park HY	36067688	2023
20	Effects of time-restricted feeding (16/8) combined with a low-sugar diet on the management of non-alcoholic fatty liver disease: A randomized controlled trial. ⁶²	Kord-Varkaneh H...Hekmatdoost A	36257081	2023
21	Incidence and Impact of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients with Adenocarcinoma of the Esophagus Treated with Curative Intent. ⁶²	Reynolds JV...Donohoe CL	36264338	2023
22	Structural optimization and biological evaluation of 1-adamantylcarbonyl-4-phenylpiperazine derivatives as FXR agonists for NAFLD. ⁶²	Qin T...Zhang L	36375336	2023
23	Offspring NAFLD liver phospholipid profiles are differentially programmed by maternal high-fat diet and maternal one carbon supplement. ⁶²	Peng H...Xie L	36270572	2023
24	Prognostic Value of Nonalcoholic Fatty Liver Disease in Patients With Severe Aortic Stenosis Who Underwent Transcatheter Aortic Valve Implantation. ⁶²	Nabeta T...Delgado V	36319504	2023
25	Exploring the active compounds and potential mechanism of the anti-nonalcoholic fatty liver disease activity of the fraction from Schisandra chinensis fruit extract based on multi-technology integrated network pharmacology. ⁶²	Li B...Liu H	36183952	2023
26	Uncovering the effect and mechanism of Panax notoginseng saponins on metabolic syndrome by network pharmacology strategy. ⁶²	Wang Y...Qiang G	36058479	2023
27	Inhibition on XBP1s-driven lipogenesis by Qushi Huayu Decoction contributes to amelioration of hepatic steatosis induced by fructose. ⁶²	Tian H...Peng J	36216198	2023
28	Different Types of Dietary Fat and Fructose Interactions Result in Distinct Metabolic Phenotypes in Male Mice. ⁶²	Shi H...Song M	36272691	2023
29	Hepatic DKK1-driven steatosis is CD36 dependent. ⁶²	Yang Z...Li YX	36410795	2023
30	Hepatic PGC-1α has minor regulatory effect on the liver transcriptome and metabolome during high fat high fructose diet and exercise training. ⁶²	Rasmussen MK...Pilegaard H	36368573	2023
31	One-step metal affinity purification of recombinant hFGF19 without using tags. ⁶²	Choi HJ...Kim GJ	36206960	2023
32	Isolation of the Hepatic Ubiquitome/NEDDylome by Streptavidin Pull-Down Assay in the Biotinylated Ubiquitin (bioUb)/Biotinylated NEDD8 (bioNEDD8) Transgenic Mice. ⁶²	Serrano-Macia M...Martinez-Chantar ML	36446973	2023
33	A method for quantifying hepatic and intestinal ceramides on mice by UPLC-MS/MS. ⁶²	Ge K...Zhao A	36375519	2023
34	The metabolic, protective, and immune functions of Akkermansia muciniphila. ⁶²	Ghotaslou R...Nezhadi J	36347103	2023
35	Side effect profile of pharmacologic therapies for liver fibrosis in nonalcoholic fatty liver disease: a systematic review and network meta-analysis. ⁶²	Li Y...Feng P	36468565	2023
36	Pharmacotherapeutic efficacy on noninvasive fibrosis progression in nonalcoholic fatty liver disease: a systematic review and network meta-analysis. ⁶²	Kovalic AJ...Satapathy SK	36468574	2023
37	Elevated serum levels of diamine oxidase, D-lactate and lipopolysaccharides are associated with metabolic-associated fatty liver disease. ⁶²	Zhang R...Liu J	36468573	2023
38	Depletion of stearoyl-CoA desaturase (scd) leads to fatty liver disease and defective mating behavior in zebrafish. ⁶²	Xu SS...Sun YH	36317480	2023
39	Genome Editing and Fatty Liver. ⁶²	Hayat U...Hameed N	36454468	2023
40	Association of serum uric acid with all-cause and cardiovascular mortality among adults with nonalcoholic fatty liver disease. ⁶²	Yang S...Qin X	35968564	2023
41	Regulatory effects mediated by ulvan oligosaccharide and its zinc complex on lipid metabolism in high-fat diet-fed mice. ⁶²	Chi Y...Li R	36372481	2023
42	Serum sex hormone-binding globulin is a mediator of the association between intrahepatic lipid content and type 2 diabetes: the Maastricht Study. ⁶²	Simons PIHG...Brouwers MCGJ	36114428	2023
43	A diet-independent zebrafish model for NAFLD recapitulates patient lipid profiles and offers a system for small molecule screening. ⁶²	Singh MK...Sachidanandan C	36202338	2023
44	Ancestral BPA exposure caused defects in the liver of medaka for four generations. ⁶²	Chakraborty S...Bhandari RK	36174697	2023
45	Physical activity is inversely associated with hepatic fibro-inflammation: A population-based cohort study using UK Biobank data. ⁶²	Sherry AP...King JA	36440257	2023
46	Comparison between obese and non-obese NAFLD. ⁶²	Chan WK	36472052	2022
47	Adlay (Coix lacryma-jobi L.) Polyphenol Improves Hepatic Glucose and Lipid Homeostasis through Regulating Intestinal Flora via AMPK Pathway. ⁶²	Ma S...Chen XY	36214059	2022
48	Identification of high-risk subjects in NAFLD. ⁶²	Stern C...Castera L	36472050	2022
49	Sex-specific associations of the urinary fourteen-metal mixture with NAFLD and liver fibrosis among US adults: A nationally representative study. ⁶²	Wan H...Shen J	36402077	2022
50	Is elevated ALT associated with lifestyle risk factors? A population-based survey. ⁶²	Balali P...Delavari A	36404851	2022

Sources

Genes for Fatty Liver Disease

Genes related to Fatty Liver Disease (2 elite genes):

(show top 50) (show all 100)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	NAFLD1	Fatty Liver Disease 1, Susceptiblity To	Genetic Locus	58.49	MalaCards inferred ³⁹ GeneCards inferred via : Gene name (show sections)
2	NAFLD2	Fatty Liver Disease, Nonalcoholic, Susceptibility To, 2	Genetic Locus	58.49	MalaCards inferred ³⁹ GeneCards inferred via : Gene name (show sections)
3	MALAT1	Metastasis Associated Lung Adenocarcinoma Transcript 1	RNA Gene	150	Experimental evidence: Regulation ³⁷	26935028
4	ADIPOQ	Adiponectin, C1Q And Collagen Domain Containing	Protein Coding	34.88	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Pathways & Interactions (show sections)	19491377 16108051 18709650 (more) 19561788 19032584 16116627
5	PPARA	Peroxisome Proliferator Activated Receptor Alpha	Protein Coding	34.7	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Pathways & Interactions (show sections)	19032584
6	CYP2E1	Cytochrome P450 Family 2 Subfamily E Member 1	Protein Coding	33.33	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Pathways & Interactions (show sections)	15670659 14606109
7	PNPLA3	Patatin Like Phospholipase Domain Containing 3	Protein Coding	28.86	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
8	INS	Insulin	Protein Coding	27.3	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)
9	SREBF1	Sterol Regulatory Element Binding Transcription Factor 1	Protein Coding	27.08	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)
10	TNF	Tumor Necrosis Factor	Protein Coding	26.65	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)
11	LEP	Leptin	Protein Coding	26.59	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)
12	NR1H4	Nuclear Receptor Subfamily 1 Group H Member 4	Protein Coding	26.2	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)
13	IL6	Interleukin 6	Protein Coding	26.18	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)
14	CCL2	C-C Motif Chemokine Ligand 2	Protein Coding	24.56	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)
15	LEPR	Leptin Receptor	Protein Coding	24.43	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)
16	IRS1	Insulin Receptor Substrate 1	Protein Coding	24.39	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)
17	NR1H3	Nuclear Receptor Subfamily 1 Group H Member 3	Protein Coding	24.26	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)
18	IRS2	Insulin Receptor Substrate 2	Protein Coding	23.85	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)
19	XBP1	X-Box Binding Protein 1	Protein Coding	23.85	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)
20	MAP3K5	Mitogen-Activated Protein Kinase Kinase Kinase 5	Protein Coding	23.58	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)
21	MAPK8	Mitogen-Activated Protein Kinase 8	Protein Coding	23.49	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)
22	DDIT3	DNA Damage Inducible Transcript 3	Protein Coding	23.28	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)
23	IL1A	Interleukin 1 Alpha	Protein Coding	23.16	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)
24	VCAM1	Vascular Cell Adhesion Molecule 1	Protein Coding	22.81	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)
25	ATF4	Activating Transcription Factor 4	Protein Coding	22.78	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)
26	INSR	Insulin Receptor	Protein Coding	22.61	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)
27	FAS	Fas Cell Surface Death Receptor	Protein Coding	22.15	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)
28	EIF2S1	Eukaryotic Translation Initiation Factor 2 Subunit Alpha	Protein Coding	21.82	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)
29	MIR122	MicroRNA 122	RNA Gene	19.82	DISEASES inferred ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)
30	GPT	Glutamic--Pyruvic Transaminase	Protein Coding	18.45	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
31	MIR21	MicroRNA 21	RNA Gene	17.94	DISEASES inferred ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)
32	MIR192	MicroRNA 192	RNA Gene	17.85	DISEASES inferred ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)
33	MIR34A	MicroRNA 34a	RNA Gene	17.84	DISEASES inferred ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)
34	TM6SF2	Transmembrane 6 Superfamily Member 2	Protein Coding	17.4	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
35	PPARG	Peroxisome Proliferator Activated Receptor Gamma	Protein Coding	17.39	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
36	FGF21	Fibroblast Growth Factor 21	Protein Coding	17.14	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
37	MIR29A	MicroRNA 29a	RNA Gene	16.54	DISEASES inferred ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)
38	SIRT1	Sirtuin 1	Protein Coding	16.47	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
39	APOB	Apolipoprotein B	Protein Coding	16.33	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
40	PPARGC1A	PPARG Coactivator 1 Alpha	Protein Coding	16.33	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
41	KRT18	Keratin 18	Protein Coding	16.28	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
42	TLR4	Toll Like Receptor 4	Protein Coding	16.23	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
43	FASN	Fatty Acid Synthase	Protein Coding	16.19	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
44	MLXIPL	MLX Interacting Protein Like	Protein Coding	16.18	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
45	MTTP	Microsomal Triglyceride Transfer Protein	Protein Coding	16.18	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
46	MBOAT7	Membrane Bound O-Acyltransferase Domain Containing 7	Protein Coding	16.14	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
47	MIR155	MicroRNA 155	RNA Gene	16.13	DISEASES inferred ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)
48	CRP	C-Reactive Protein	Protein Coding	16.11	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
49	RETN	Resistin	Protein Coding	16.09	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
50	MIR181B1	MicroRNA 181b-1	RNA Gene	16.06	DISEASES inferred ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)

Sources

Variations for Fatty Liver Disease

Sources

Expression for Fatty Liver Disease

Search GEO for disease gene expression data for Fatty Liver Disease.

Sources

Pathways for Fatty Liver Disease

Pathways related to Fatty Liver Disease according to GeneCards Suite gene sharing:

(show all 39)

#	Super pathways	Score	Top Affiliating Genes
1	Signal Transduction ⁶⁶	13.75	CCL2 IL6 INS IRS1 IRS2 LEP
2	IL-9 Signaling Pathways ⁶⁵ Show member pathways Adipocytokines and Insulin Signaling ⁶⁵ Common Cytokine Receptor Gamma-Chain Family Signaling Pathways ⁶⁵ Development Thrombopoietin-regulated cell processes ²² IL-15 Signaling Pathways ⁶⁵ IL-2 Signaling Pathways ⁶⁵ IL-21 Signaling Pathways ⁶⁵ IL-4 Pathway ⁶⁴ IL-4 Signaling Pathways ⁶⁵ IL-7 Signaling Pathways ⁶⁵ IL-9 Pathway ⁶⁴ Immune response IL-9 signaling pathway ²² Interleukin-9 signaling ⁶⁶	12.82	ADIPOQ IL6 INS IRS1 IRS2 LEP
3	Alzheimer's disease and miRNA effects ⁷⁴ Show member pathways Alzheimer's disease ⁷⁴	12.74	IL6 INS IRS1 IRS2 MAP3K5 TNF
4	Nuclear receptors meta-pathway ⁷⁴ Show member pathways NRF2 pathway ⁷⁴	12.64	TNF SREBF1 PPARA NR1H4 NR1H3 IRS2
5	Glucose / Energy Metabolism ³	12.51	SREBF1 IRS2 IRS1 INS ADIPOQ
6	Angiopoietin-like protein 8 regulatory pathway ⁷⁴ Show member pathways Insulin signaling ⁷⁴ Liver X receptor pathway ⁷⁴	12.45	XBP1 SREBF1 NR1H3 MAP3K5 IRS2 IRS1
7	PPARA activates gene expression ⁶⁶ Show member pathways Regulation of lipid metabolism by PPARalpha ⁶⁶ Transcriptional regulation of white adipocyte differentiation ⁶⁶	12.37	ADIPOQ LEP NR1H3 NR1H4 PPARA SREBF1
8	Apoptosis and survival FAS signaling cascades ²² Show member pathways Apoptosis and survival Caspase cascade ²² Breakdown of the nuclear lamina ⁶⁶ Caspase Cascade in Apoptosis ⁶¹ Fas ligand pathway and stress induction of heat shock proteins ⁷⁴ Fas Signaling ⁶⁴	12.32	TNF SREBF1 MAP3K5 IRS1
9	AMPK Enzyme Complex Pathway ⁶⁴ Show member pathways Chromatin Remodeling ⁶⁴	12.17	LEP IRS2 IRS1 INS
10	AMP-activated protein kinase signaling ⁷⁴ Show member pathways AMPK Signaling Pathway ⁶⁷ Leptin and adiponectin ⁷⁴	12.07	SREBF1 LEPR LEP INS ADIPOQ
11	Spinal cord injury ⁷⁴	11.98	TNF LEP IL6 CCL2
12	Mesenchymal Stem Cells and Lineage-specific Markers ⁶⁵	11.88	ADIPOQ IL6 INS LEP
13	Interferon Pathway ⁶⁴	11.84	MAP3K5 IRS2 IRS1 IL6
14	PPAR signaling pathway ⁷⁴ Show member pathways FABP4 in ovarian cancer ⁷⁴ Fatty acid transporters ⁷⁴	11.79	PPARA NR1H3 ADIPOQ
15	Burn wound healing ⁷⁴	11.72	TNF IL6 CCL2
16	Extrafollicular B cell activation by SARS-CoV-2 ⁷⁴	11.7	XBP1 TNF IL6
17	Lung fibrosis ⁷⁴	11.64	TNF IL6 CCL2
18	Non-genomic actions of 1,25 dihydroxyvitamin D3 ⁷⁴	11.54	CCL2 IL6 TNF
19	Development_Leptin signaling via PI3K-dependent pathway ²²	11.54	LEPR LEP IRS2 IRS1
20	Nonalcoholic fatty liver disease ⁷⁴	11.52	ADIPOQ CCL2 CYP2E1 IL6 INS IRS1
21	Interleukin-10 signaling ⁶⁶	11.49	TNF IL6 CCL2
22	Adipogenesis ⁷⁴	11.48	ADIPOQ IL6 INS IRS1 IRS2 LEP
23	White fat cell differentiation ⁷⁴ Show member pathways Transcriptional cascade regulating adipogenesis ⁷⁴	11.45	SREBF1 NR1H3 INS
24	Fibrin complement receptor 3 signaling pathway ⁷⁴	11.45	TNF IL6 CCL2
25	Signaling events mediated by PTP1B ⁶¹	11.42	LEPR LEP IRS1 INS
26	Antiviral and anti-inflammatory effects of Nrf2 on SARS-CoV-2 pathway ⁷⁴	11.28	TNF IL6 CCL2
27	Nuclear receptors in lipid metabolism and toxicity ⁷⁴	11.25	PPARA NR1H4 NR1H3 CYP2E1
28	Prostaglandin signaling ⁷⁴	11.23	TNF IL6 CCL2
29	Anti-diabetic Drug Potassium Channel Inhibitors Pathway, Pharmacodynamics ⁶⁰	11.23	IRS2 IRS1 INS
30	Type II diabetes mellitus ⁷⁴	11.11	TNF IRS1 ADIPOQ
31	Leptin-insulin signaling overlap ⁷⁴ Show member pathways Signaling by Leptin ⁶⁶	11.1	LEPR LEP IRS2 IRS1 INS
32	FOXA2 pathway ⁷⁴	11.05	SREBF1 IRS2 IRS1
33	Antipsychotics Pathway (Metabolic Side Effects), Pharmacodynamics ⁶⁰	11.04	LEPR LEP INS
34	Roles of ceramides in the development of insulin resistance ⁷⁴	11.01	TNF IRS2 IRS1 INS
35	Transcription factor regulation in adipogenesis ⁷⁴	10.98	TNF LEP IRS2 IRS1 IL6 ADIPOQ
36	SREBF and miR33 in cholesterol and lipid homeostasis ⁷⁴	10.94	SREBF1 PPARA NR1H3
37	RXR and RAR heterodimerization with other nuclear receptor ⁶¹	10.87	TNF SREBF1 NR1H4
38	COVID-19 adverse outcome pathway ⁷⁴	10.68	IL6 CCL2
39	Cells and molecules involved in local acute inflammatory response ⁷⁴ Show member pathways IL8-mediated signaling events ⁶¹	10.35	TNF IL6

Sources

GO Terms for Fatty Liver Disease

Biological processes related to Fatty Liver Disease according to GeneCards Suite gene sharing:

(show all 36)

#	Name	GO ID	Score	Top Affiliating Genes
1	lipid metabolic process	GO:0006629	10.27	XBP1 SREBF1 PNPLA3 NR1H3 LEP CYP2E1
2	negative regulation of inflammatory response	GO:0050728	10.24	PPARA NR1H4 NR1H3 ADIPOQ
3	positive regulation of MAPK cascade	GO:0043410	10.24	IL6 INS LEP MAP3K5 TNF
4	positive regulation of interleukin-6 production	GO:0032755	10.21	XBP1 TNF LEP IL6
5	circadian rhythm	GO:0007623	10.2	TNF SREBF1 LEP ADIPOQ
6	response to bacterium	GO:0009617	10.19	TNF CYP2E1 CCL2 ADIPOQ
7	positive regulation of protein kinase B signaling	GO:0051897	10.18	XBP1 TNF LEP INS
8	insulin receptor signaling pathway	GO:0008286	10.18	SREBF1 IRS2 IRS1 INS
9	positive regulation of protein phosphorylation	GO:0001934	10.18	ADIPOQ LEP LEPR MAP3K5 TNF XBP1
10	positive regulation of interleukin-8 production	GO:0032757	10.17	TNF LEP IL6 ADIPOQ
11	cellular response to lipopolysaccharide	GO:0071222	10.11	CCL2 IL6 NR1H3 NR1H4 TNF XBP1
12	positive regulation of receptor signaling pathway via JAK-STAT	GO:0046427	10.1	TNF LEP IL6
13	response to activity	GO:0014823	10.1	TNF LEP IL6 ADIPOQ
14	cellular response to fatty acid	GO:0071398	10.08	SREBF1 NR1H4 IRS1
15	positive regulation of vascular associated smooth muscle cell proliferation	GO:1904707	10.06	XBP1 TNF MAP3K5
16	negative regulation of gluconeogenesis	GO:0045721	10.06	LEPR INS ADIPOQ
17	regulation of insulin secretion	GO:0050796	10.05	TNF SREBF1 LEP IL6
18	fatty acid homeostasis	GO:0055089	10.03	XBP1 NR1H4 INS
19	intracellular receptor signaling pathway	GO:0030522	10.03	SREBF1 PPARA NR1H4 NR1H3
20	positive regulation of glycogen biosynthetic process	GO:0045725	10.02	INS IRS1 IRS2
21	negative regulation of macrophage derived foam cell differentiation	GO:0010745	10.01	PPARA NR1H3 ADIPOQ
22	positive regulation of glucose import	GO:0046326	10.01	IRS2 IRS1 INS ADIPOQ
23	positive regulation of fatty acid beta-oxidation	GO:0032000	10	PPARA IRS2 IRS1
24	response to sucrose	GO:0009744	9.96	PNPLA3 ADIPOQ
25	regulation of bone remodeling	GO:0046850	9.96	LEPR LEP
26	glucose metabolic process	GO:0006006	9.96	TNF LEP IRS2 INS ADIPOQ
27	positive regulation of fatty acid metabolic process	GO:0045923	9.95	ADIPOQ PPARA
28	bone growth	GO:0098868	9.94	LEP LEPR
29	negative regulation of lipid storage	GO:0010888	9.93	TNF LEP IL6
30	response to ethanol	GO:0045471	9.93	ADIPOQ CYP2E1 LEP PPARA SREBF1 TNF
31	sterol homeostasis	GO:0055092	9.92	XBP1 NR1H3
32	lipid localization	GO:0010876	9.92	PPARA SREBF1
33	positive regulation of insulin receptor signaling pathway	GO:0046628	9.92	NR1H4 LEP IRS1 INS
34	regulation of lipid storage	GO:0010883	9.84	SREBF1 PPARA
35	glucose homeostasis	GO:0042593	9.77	NR1H4 LEPR LEP IRS1 INS IL6
36	cellular response to insulin stimulus	GO:0032869	9.44	XBP1 SREBF1 PNPLA3 LEP IRS2 IRS1

Molecular functions related to Fatty Liver Disease according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	sterol response element binding	GO:0032810	9.46	SREBF1 NR1H3
2	insulin receptor binding	GO:0005158	9.43	IRS2 IRS1 INS
3	nuclear receptor activity	GO:0004879	9.23	SREBF1 PPARA NR1H4 NR1H3